Anupam Rasayan India Limited
Anupam Rasayan India Ltd is engaged in manufacturing of specialty chemicals, which are sold in local as well as exported to other countries.
What Anupam files
- Others71
- Investor Meet34
- Updates30
- Board Meeting15
- PPTs10
- Important9
Anupam Rasayan (ANURAS) kicked off FY27 strongly. **Business Performance:** Consolidated revenue jumped 36% YoY to ₹667.5 Cr, driven by new products and healthy demand across segments. Consolidated EBITDA grew 35% YoY to ₹174.9 Cr, with PAT up 6% YoY to ₹51.2 Cr. EPS stood at ₹3.40. Growth was strong in...
Anupam Rasayan is acquiring a controlling stake in Bliss GVS Pharma, a well-established pharmaceutical formulations company known for its branded products across 50+ therapeutic segments. Bliss GVS holds strong global accreditations, including US FDA and EU GMP approvals. **Business Performance:** Bliss GVS's revenue grew from 752 Cr in FY23 to...
**Business Performance:** Anupam Rasayan delivered its highest-ever annual performance in FY26, with consolidated revenue reaching ₹2,383.6 Cr, a 65% YoY jump. Consolidated Profit After Tax (PAT) grew significantly by 39% to ₹222.2 Cr. For Q4FY26, consolidated revenue was ₹639.2 Cr (+26% YoY), though PAT saw an 11% de-growth to ₹56...
Anupam Rasayan (ANURAS) posted strong Q3 & 9M FY26 financial results. Consolidated revenue for the nine-month period surged 84% YoY to ₹1,729.7 Cr, with PAT up 71% to ₹166.2 Cr. Quarterly consolidated revenue grew 31% to ₹512.4 Cr, and PAT rose 12% to ₹60.6 Cr, fueled by new molecule ramp-ups...
Anupam Rasayan is acquiring 100% equity in US-based specialty chemical firm Jayhawk Fine Chemicals LLC for an enterprise value of ~$134 million. Jayhawk reported ~$78 million revenue and ~$15 million EBITDA (19% margins) in CY24. This strategic move significantly strengthens Anupam's US presence, expanding its portfolio into high-value performance materials...